Ultra sensitive method for the determination of 9-(2- phosphonylmethoxyethyl)adenine in human serum by liquid chromatography-tandem mass spectrometry

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 803, Issue 2, 2004, Pages 293-298

  Liu, Yifei ^a   Xu, Guifen ^a   Xu, Christine ^a   Garcia, Liset ^a   Lin, Chin Chung ^a   Yeh, Li Tain ^a  

^a Ribapharm Inc   (United States)

Author keywords

9 (2 Phosphonylmethoxyethyl)adenine

Indexed keywords

BODY FLUIDS; DRUG PRODUCTS; EXTRACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY;

ANTIVIRAL AGENTS; HUMAN SERUM;

AROMATIC COMPOUNDS;

ADEFOVIR; ANTIVIRUS AGENT; CARBON 13;

ACCURACY; ARTICLE; ASSAY; CONCENTRATION (PARAMETERS); DRUG DETERMINATION; ELECTROSPRAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MEASUREMENT; MONITOR; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SERUM; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY;

ADENINE; ANTIVIRAL AGENTS; CHROMATOGRAPHY, LIQUID; HUMANS; MASS SPECTROMETRY; PHOSPHONIC ACIDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 1842531373     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2004.01.012     Document Type: Article

References (17)

1. De Clercq E., Holy A., Rosenberg I., Sakuma T., Balzarini J., Maudgal P.C. Nature. 323:1986;464-467.
2. De Clercq E. Biochem. Pharmacol. 42:1991;963-972.
3. De Clercq E. Clin. Microbiol. Rev. 8:1995;200-239.
4. Naesens L., Balzarini J., De Clercq E. Rev. Med. Virol. 4:1994;147-159.
5. J.E. Starrett, M.M. Mansuri, J.C. Martin, D.R. Tortolani, J.J. Bronson, European Patent 481,214,A1 (April 1992).
6. Cundy K.C., Shaw J.P., Lee W.A. Antimicrob. Agents Chemother. 38:1994;365-368.
7. Cundy K.C., Barditch-Crovo P., Walker R.E., Collier A.C., Ebeling D., Toole J., Jaffe H.S. Antimicrob. Agents Chemother. 39:1995;2401-2405.
8. Kahn J., Lagakos S., Wulfsohn M., Cherng D., Miller M., Cherrington J., Hardy D., Beall G., Cooper R., Murphy R., Basgoz N., Ng E., Deeks S., Winslow D., Toole J.J., Coakley D. JAMA. 282:1999;2305-2312.
9. E.J. Heathcote, L. Jeffers, T. Wright, Loss of serum HBV DNA and HbeeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B; two placebo-controlled phase II studies, Hepatology 28 (suppl. 317A).
10. E.J. Heathcote, L. Jeffer, R. Perrilo, T. Wright, M. Sherman, R. Gilson, A.O. Shakil, H. Namini, C. James, V. Ho, J. Fry, C. Brosgart, Serum HBV DNA suppression and seroconversion following long-term adefovir dipivoxil therapy in chronic hepatitis B patients, Hepatology 34 (316A).
11. FDA Advisory Committee Briefing Document, NDA 21-449, Adefovir Dipivoxil for the Treatment of Chronic Hepatitis B, Gilead Science, Foster City, CA, July 2002, p. 86.
12. Augustijns P., Annaert P., Adriaens S., De Clercq E., Kinget R. J. Liq. Chromatogr. Rel. Technol. 19:1996;2271-2283.
13. Naesens L., Balzarini J., Bischofberger N. Antimicrob. Agents Chemother. 40:1996;22-28.
14. Cundy K.C. Clin. Pharmacokinet. 36:1999;127-143.
15. Shaw J.P., Louie M.S., Krishnamurthy V.V., Arimilli M.N., Jones R.J., Bidgood A.M., Lee W.A., Cundy K.C. Drug Metabol. Dispos. 25:1996;362-366.
16. Cundy K.C., Sue I.-L., Visor G.C., Marshburn J., Nakamura C., Lee W.A., Shaw J.-P. J. Pharm. Sci. 86:1997;1334-1338.
17. Barditch-Crovo P., Toole J., Hendrix C.W., Cundy K.C., Ebeling D., Jaffe H.S., Lietman P.S. J. Infectious Diseases. 176:1997;406-413.